You can buy or sell Replimune and other stocks, options, and ETFs commission-free!
Replimune Group, Inc. Common Stock, also called Replimune, is a clinical-stage biotechnology company, which engages in the development of oncolytic immunotherapy product candidates through immulytic platform. Oncolytic immunotherapy is a cancer treatment that exploits the ability of certain viruses to selectively replicate in and directly kill tumors, as well as induce a potent, patient-specific, anti-tumor immune response. The company was founded by Philip Astley-Sparke, Colin Love and Robert Coffin in March 2015 and is headquartered in Woburn, MA. The listed name for REPL is Replimune Group, Inc. Common Stock.
52 Week High
52 Week Low
— per share
Expected Feb 11, Pre-Market